Blackstone commits $250m to back new CAR T-cell therapies

Blackstone Life Sciences is investing $250 million toward developing CAR T-cell therapies for immuno-oncology and autoimmune diseases, forming a new company structured to handle clinical-stage cell therapies along with Intellia Therapeutics and Germany's Cellex Cell Professionals GmBH.

Officials said the new company will combine GEMoaB’s clinical-stage universal CAR-T platforms with Intellia’s allogeneic cell platform and CRISPR cell engineering.

The headquarters for the new company will be in life sciences hub Cambridge, Massachusetts, where Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available.

Get started

Back to top button

Get our daily news digest
in your inbox

Our FREE mailing list brings you daily alts intel.

Thank you for subscribing.

Something went wrong.